01.04.2013.

A plague o' both your houses

Evergreening - the process of making minor changes to the existing drugs in order to get new patents and prevent generic production.
 
 
I know that what I'm about to write is completely opposite to the claims I made in some previous posts but whatever. I mean, there was this occupy wall street thing, and I was like, I don't really give a fuck. Not even a tiny one.
 
I mean, I care a little about, say, gay rights - it still kinda upsets me when a majority denies a minority some basic stuff in the name of whatever. Digression: Dr. Carson, you may believe that some god created marriage between a man and a woman as much as you like but guess what, that god didn't create the constitution so I don't really think that... well, that's about how much I really care
.
 
Then, there's this corporate greed which is actually killing us in more ways than we'll ever know but still, I'm like annoyed with say horseshit... umm... horse meat in the beefburger and equally peeved when a delivery guy on a bike almost runs me over in the middle of the sidewalk. It's like fuck you and that's it.
 
Pharma, tho...  Gods, old and new, how I hate those guys. It's like you know those games what if you're omnipotent for a day or such... well, let's say that I'd have a special day of fun playing with the lot of them... fucking bloodsuckers. Because th... ya know what? Fuck this shit!  





Fun facts:

Patents usually protect the companies for 20 years of exclusive sales. After that, it is open to other firms who can make cheaper copies of the original drug.

Once the protection expires, the first company to challenge the patent gets an exclusive right to sell the copy for 180 days.

After 180 days, more companies can sell the generic versions, potentially resulting in a further price drop.

It is estimated that drugs with combined annual sales of $150bn will go off-patent by 2015.

Glivec, which is used to treat chronic myeloid leukaemia and other cancers, costs about $2,600 (£1,710) a month.

The generic equivalent is currently available in India for just $175.

The court’s ruling confirmed that India’s criteria for the granting of such patents remain far higher than those in the United States, where patents are so easy to win that one was given in 1999 for a peanut butter-and-jelly sandwich. Which country’s patent system does more to protect the sick and encourage invention has become an increasing source of international debate.

(sources: NY Times, BBC, 4/1/13)